How have NVAX and TRVI total returns compared?

Over the past 5 years, NVAX delivered -40.61% and TRVI delivered 61.74% annualized total return. Past performance doesn't predict future results.

Novavax, Inc. (NVAX) vs Trevi Therapeutics, Inc. (TRVI)

A side-by-side comparison of Novavax, Inc. and Trevi Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

NVAX

Novavax, Inc.

$1.86B

$11.32HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

TRVI

Trevi Therapeutics, Inc.

$1.87B

$13.18HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

Total return — NVAX vs TRVI

growth of $100 · dividends reinvested · last 7y

NVAX +33.6% (+4.2%/yr)TRVI +73.9% (+8.2%/yr)TRVI compounded faster over this window

NVAX TRVI

NVAX vs TRVI: by the numbers

•TRVI is the larger company ($1.87B vs $1.86B market cap).
•Both run net losses; TRVI's is the smaller (0.00% vs -59.87% net margin).

Metrics side by side

Valuation

Metric	NVAX	TRVI
P/S ratio	4.50	N/A
P/B ratio	N/A	5.82

Profitability

Metric	NVAX	TRVI
Gross margin	93.67%	0.00%
Operating margin	50.14%	0.00%
Net margin	-59.87%	0.00%
ROE	N/A	-15.90%
ROIC	-36.37%	-18.51%

Growth (annualized)

Metric	NVAX	TRVI
Revenue CAGR (5Y)	118.86%	N/A
Total return CAGR (5Y)	-40.61%	61.74%

Frequently asked

How have NVAX and TRVI total returns compared?: Over the past 5 years, NVAX delivered -40.61% and TRVI delivered 61.74% annualized total return. Past performance doesn't predict future results.

Go deeper

Full NVAX analysis Full TRVI analysis Interactive comparison tool

Dig into the metrics

Novavax ROE Trevi Therapeutics ROE Novavax operating margin Trevi Therapeutics operating margin Novavax revenue growth Trevi Therapeutics revenue growth Novavax free cash flow Trevi Therapeutics free cash flow

Novavax & Trevi Therapeutics appear in these rankings

Fastest Revenue Growth Stocks Highest Operating Margin Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.